Manufacturing companies are charging ahead to buy powerful AI tools, yet many teams can’t keep pace. What’s next for AI and ...

GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...